Shukra Pharmaceuticals Ltd

Name change and MOA amendments

• Approved change of company name to Shukra Medtech Limited, subject to regulatory and shareholder approvals.
• Authorized any director or KMP to file prescribed form in ROC Ahmedabad.
• Reservation of proposed name from Shukra Pharmaceuticals Limited to Shukra Medtech Limited.
• Approved alteration in main objects and MOA, subject to postal ballot and approvals.
• Details provided in Annexure-I and Annexure-II.

Postal ballot, notices, and AGM actions

• Draft notice for postal ballot approved to obtain shareholders' approval for name and MOA changes.
• CS Rupal Patel appointed as Scrutinizer for e-voting and AGM voting.
• Director's Report and Secretarial Audit Report for year ended 31 March 2026 approved.
• AGM convened for 25 September 2026 at 12:00 PM IST via VC.
• Register of Members and Share Transfer Books closed 19–25 September 2026.
• Draft AGM notice approved.

MOA/AOA amendments and regulatory disclosures

• Name change contingent on CRC and other approvals; subject to General Meeting approval and MOA/AOA amendments.
• MOA amendments add main objects for MedTech research and manufacturing.
• New sub-clauses outline alliances, licensing, healthcare software, AI, and digital health activities.
• Additional clauses authorize co-development, licensing, franchises, and OEM agreements.
• All actions subject to required regulatory and shareholder approvals.

NSE listing update

• Aug 14, 2026: Shukra Pharmaceuticals' equity shares listed on NSE; dual listing with BSE.
• ANI article on listing highlights strategic direction in medical tech, AI, and healthcare innovation.
• Company clarifies article is media coverage and not a new material agreement, contract, order, or investment.
• Any material transaction will be disclosed separately under applicable laws.
• Regulatory disclosures under Regulation 30 will continue for any material event.
• Listing milestone supports the company’s technology-focused growth strategy and broader capital market presence.
• No new material agreements disclosed as of the date.

Meeting Details

• Date: August 22, 2026; Location: Registered Office; Time: not disclosed.

Key Agenda Items

• Change of name of the company subject to shareholder approval.
• Change in object clause and alteration to MOA subject to shareholder approval.
• Draft Postal Ballot notice for member consent; to be submitted to stock exchanges under SEBI Listing Regulations.
• Appointment of Mrs. Rupal Patel as Scrutinizer for postal ballot.
• Draft Director's Report and Secretarial Audit Report for year ended March 31, 2026.
• Fix day, date, time and venue for Annual General Meeting.
• Decide on dates for closure of Register of Members and Share Transfer Register for annual book closure.
• Draft notice for Annual General Meeting.
• Appoint Scrutinizer for remote e-voting and AGM voting.
• Any other business with permission of Chairman.

JV purpose and parties

• Term Sheet with Borns Medical Robotics to form a strategic JV in India and APAC.
• JV named B&S Robotics Private Limited; Shukra 60%, Borns 40%.
• Borns proposed as Singapore-incorporated holding entity for the JV.
• Post-certifications (USFDA/CE), expansion to rest of the world.

Governance and definitive terms

• Board of five: Shukra 3 seats, Borns 2; to be set out in SHA/AoA.
• Initial paid-up capital TBD; equity ratio 60:40.
• Definitive agreements planned: SHA, AoA, IP licensing, sub-license, royalty, and more.
• Exclusivity provisions binding for the primary Territory in surgical robotics.
• Term Sheet non-binding except confidentiality, exclusivity, costs, and governing law.
• Potential future demerger/listing pathway for JV; not guaranteed.

Timeline, regulatory, and financial impact

• Long form agreements targeted within ~120 days from execution.
• Conditions precedent: Borns Singapore entity, due diligence, valuation, FEMA/FDI clearances, approvals.
• Regulatory approvals: FEMA/FDI, CDSCO and other applicable clearances.
• No fixed immediate investment; financial impact defined in definitive agreements.
• JV is not in ordinary course; disclosed under LODR.
• Further disclosures to exchanges when definitive agreements executed or material developments occur.

Proposed name change and MOA expansion

• Board approved name change to Shukra Medtech Limited, subject to regulatory approvals.
• Expansion of Main Objects to enable MedTech activities across development, manufacturing, distribution, and marketing.
• Subject to shareholders' approval and other permissions under applicable laws and SEBI LODR.
• Intends broader corporate identity and opportunities in medical technology beyond pharmaceutical activities.
• Disclosures on name change and MOA alterations to be provided when applicable.
• Board meeting date August 14, 2026; approvals contingent on statutory/regulatory clearance.

NSE listing details

• Equity shares listed and admitted to dealings on NSE Main Board from 14 August 2026.
• NSE trading symbol: SHUKRAPHAR; ISIN: INE551C01044; Market: Main Board - Equity.
• Shares will continue to be listed on BSE; dual listing aims to enhance liquidity and investor base.
• Base reference price on NSE determined by closing price on BSE as of 13 August 2026.

Direct NSE listing

• Equity shares approved for listing and regular trading on the NSE Main Board.
• Direct listing from BSE; NSE trading to commence 14 August 2026.
• NSE trading symbol SHUKRAPHAR, ISIN INE551C01044, Main Board - Equity.
• Base reference price derived from BSE closing price on August 13, 2026.
• Dual-listing aims to broaden investor base and deepen liquidity.

Board approval & audit status

• Unaudited standalone and consolidated Q1 FY2026 results approved; quarter ended 30 June 2026.
• Audit Committee reviewed results; Shah Sanghvi & Associates performed the limited review.
• Two segments: Shukra Pharmaceutical and Shukra MedTech, MedTech renamed Oct 1, 2025.

Key financial highlights

• Standalone Q1 FY2026: total income 2,406.20 Lakhs, net profit 1,502.98 Lakhs.
• Consolidated Q1 FY2026: total income 2,406.20 Lakhs, net profit 1,295.85 Lakhs.
• Investor complaints during quarter: none reported.

Regulatory disclosures

• SEBI LODR Regulation 33 compliant interim results; disclosed on company and BSE websites.
• Independent auditor review reports state no material misstatement.
• No investor complaints pending as of June 30, 2026.

Warrant differential receipt and pricing compliance

• Differential upfront Rs 0.39 per warrant (Rs 18,10,770 total) received within 15 days.
• Allottees paid the 25% upfront by July 13, 2026.
• 4,643,000 warrants allotted on January 28, 2026 are in full compliance with ICDR pricing.
• Balance 75% of warrant issue price payable at exercise/conversion.
• Two allottees paid balance differential Rs 20,29,950 by July 13, 2026.
• Total differential receipt confirmed under Regulation 170(2) of ICDR Regulations.
• Allottees include promoter individuals and promoter-group entities.